Danish-Swedish biotech company 2A Pharma has taken the company's HPV vaccine into clinical development in record time. If everything goes well, the vaccine will enter a billion-dollar market in five years. "We have the potential to become quite big," says CEO.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.